NPS teams with Allergan to promote Restasis to rheumatologists

By E. Janene Geiss

Philadelphia, Oct. 24 - NPS Pharmaceuticals, Inc. announced Monday that it would partner with Allergan, Inc. to promote prescription eye drop Restasis to rheumatologists for patients with chronic dry eye disease.

The deal calls for Allergan to supply promotional materials, training and other support to NPS rheumatology sales professionals who will begin promoting the eye drop next month to doctors in the United States, according to a company news release.

"It expands our product line in rheumatology and gives us an important new product to offer rheumatologists and their patients with chronic dry eye disease," Dr. Hunter Jackson, chairman, president and chief executive officer of NPS, said in the release.

The NPS sales force is preparing to launch promotion of Preos, a drug candidate under Federal Drug Administration review for osteoporosis.

Allergan will continue to promote Restasis to ophthalmologists and optometrists through its own sales force and direct-to-consumer advertising.

NPS is a pharmaceutical company based in Salt Lake City.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.